


WHAT IS CLAIMED IS:

1. A compound of the following formula A-3:



A-3

wherein,

R_1 is haloalkyl, hydroxyalkyl, haloalkenyl, heterocycloalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted phenylamino, unsubstituted benzyl, alkoxyalkyl, poly(alkoxy)alkyl, hydroxyalkoxyalkyl, hydroxypoly(alkoxy)alkyl, haloalkoxyalkyl, halopoly(alkoxy)alkyl, or aminoalkyl.

2. A compound according to claim 1 which is in the form of a pharmaceutically acceptable salt thereof.


3. A compound according to claim 2 wherein said pharmaceutically acceptable salt is hydrochloride salt.

4. A compound according to claim 1 which is in the form of a prodrug thereof.

5. A compound according to claim 1 which is in the form of a liposome delivery system.

6. A compound according to claim 6 wherein R_1 is alkyl or substituted or unsubstituted phenyl.

7. A pharmaceutical composition comprising a therapeutically effective amount of a compound of the following formula A-3:



wherein,

R₁ is alkyl, haloalkyl, hydroxyalkyl, alkenyl, haloalkenyl, cycloalkyl, cycloalkalkyl, heterocycloalkyl, heterocycloalkalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted phenylamino, substituted or unsubstituted benzyl, alkoxyalkyl, poly(alkoxy)alkyl, hydroxyalkoxyalkyl, hydroxypoly(alkoxy)alkyl, haloalkoxyalkyl, halopoly(alkoxy)alkyl, or aminoalkyl; and, a pharmaceutically acceptable carrier.

8. A pharmaceutical composition according to claim 7 ~~which is~~ in the form of a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition according to claim 8 wherein said pharmaceutically acceptable salt is selected from the group consisting of chloride, bromide, sulfate, nitrate, phosphate, sulfonate, formate, tartrate, maleate, malate, citrate, benzoate, salicylate, ascorbate, and mixtures thereof.

10. A pharmaceutical composition according to claim 8 wherein said pharmaceutically acceptable salt is hydrochloride salt.

11. A pharmaceutical composition according to claim 7 ~~which is~~ in the form of a prodrug thereof.

12. A pharmaceutical composition according to claim 7 which is in the form of a liposome delivery system.

13. A pharmaceutical composition according to claim 7 wherein said compound is micronized and said composition is suitable for administration by injection.


5 14. A pharmaceutical composition according to Claim 7 wherein said compound is coupled to a soluble polymer.

15. A pharmaceutical composition according to Claim 7 wherein said compound is coupled to a biodegradable polymer.

10

16. A pharmaceutical composition according to Claim 7 wherein R₁ is alkyl or substituted or unsubstituted phenyl.

15 17. A pharmaceutical composition comprising a therapeutically enhanced amount of a compound of the following formula A-3:



A-3

wherein,

20


R₁ is alkyl, haloalkyl, hydroxyalkyl, alkenyl, haloalkenyl, cycloalkyl, cycloalkalkyl, heterocycloalkyl, heterocycloalkalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted phenylamino, substituted or unsubstituted benzyl, alkoxyalkyl, poly(alkoxy)alkyl, hydroxyalkoxyalkyl, hydroxypoly(alkoxy)alkyl, haloalkoxyalkyl, halopoly(alkoxy)alkyl, or aminoalkyl;

25

a therapeutically effective amount of a chemotherapeutic agent;
and, a pharmaceutically acceptable carrier.

18. A pharmaceutical composition according to claim 17 which further comprises a therapeutically effective amount of a potentiator.

19. A unit dosage form comprising a compound of the following formula A-3:



A-3

wherein,

R_1 is alkyl, haloalkyl, hydroxyalkyl, alkenyl, haloalkenyl, cycloalkyl, cycloalkalkyl, heterocycloalkyl, heterocycloalkalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted phenylamino, substituted or unsubstituted benzyl, alkoxyalkyl, poly(alkoxy)alkyl, hydroxyalkoxyalkyl, hydroxypoly(alkoxy)alkyl, haloalkoxyalkyl, halopoly(alkoxy)alkyl, or aminoalkyl;

and, a pharmaceutically acceptable carrier.

20. A unit dosage form according to claim 19 which comprises from 1 mg to 1000 mg of said compound.


21. A unit dosage form according to claim 19 which is in the form of a liposome delivery system.

22. A unit dosage form according to claim 19 wherein said compound is micronized and said carrier is suitable for administration by injection.

23. A unit dosage form according to claim 19 wherein said compound is coupled to a soluble polymer.

24. A unit dosage form according to claim 19 wherein said compound is coupled to a biodegradable polymer.

25. A pharmaceutical kit comprising:
a therapeutically effective amount of a compound of the following formula A-3:



A-3

wherein,

R₁ is alkyl, haloalkyl, hydroxyalkyl, alkenyl, haloalkenyl, cycloalkyl, cycloalkalkyl, heterocycloalkyl, heterocycloalkalkyl, substituted or unsubstituted phenyl, substituted or unsubstituted phenylamino, substituted or unsubstituted benzyl, alkoxyalkyl, poly(alkoxy)alkyl, hydroxyalkoxyalkyl, hydroxypoly(alkoxy)alkyl, haloalkoxyalkyl, halopoly(alkoxy)alkyl, or aminoalkyl;
and, instruction for use in treating cancer or a viral infection.